drugset / Trial / NCT00210015

A Study in Subjects With Perennial Allergic Rhinitis

NCT00210015 ↗

Phase 2 Completed 630 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to determine the efficacy and safety of the study drug compared to placebo for the treatment of subjects with perennial allergic rhinitis.

Timeline

Start
2002-12
Primary completion
2003-04
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject INS37217 Unknown — Intranasal